February 5, 2008

Aqua Bounty signs immune stimulant agreement with Stirling Products
 

Aqua Bounty Technologies Inc, has signed a term sheet with Stirling Products North America for exclusive distribution option of ProVale in Chilean salmon market.
 

Aqua Bounty will handle field trials required for proof of efficacy and market approval of ProVale, an immune stimulant that is used for disease management in fish. ProVale will be tested as replacement for antibiotics in the diets of farmed salmon.

The trials are expected to commence soon and are currently waiting for regulatory approval. The trials will last for two to three months during which Aqua Bounty will work with Stirling Products to finalise a commercial distribution agreement.

The partnership will allow penetration of the Chilean salmon market, which produces one third of farmed salmons that are valued at over US$4.5 billion.

Initial market value in Chile for ProVale is expected to be at least US$3 million per year.

CEOs of Aqua Bounty and Stirling Products have expressed their happiness at signing the agreement.

Dr Calvin London, CEO and managing director of Stirling Products North America said the collaboration would provide additional revenue potential and opportunities for future developments of specialised feeds and disease protection formulations for farmed fish.